Compare · HUM vs YDES
HUM vs YDES
Side-by-side comparison of Humana Inc. (HUM) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $48.03B, about 172.8x YDES ($278.0M).
- Over the past year, HUM is up 47.1% and YDES is down 76.5% - HUM leads by 123.5 points.
- HUM has been more active in the news (7 items in the past 4 weeks vs 3 for YDES).
- HUM has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Humana Inc.
- YD Bio Limited
- Price
- $401.11-0.47%
- $3.68-11.96%
- Market cap
- $48.03B
- $278.0M
- 1M return
- +4.09%
- +46.91%
- 1Y return
- +47.06%
- -76.46%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 3
- Recent ratings
- 25
- 0
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest HUM
- Chief Medical Officer Nundy Shantanu was granted 2,549 units of Humana Common (SEC Form 4)
- Humana Earns 2026 Great Place To Work Certification™ and PEOPLE Companies That Care® Recognition
- Humana Board Declares Payment of Quarterly Dividend to Stockholders
- Humana Foundation Names 2026 Scholarship Recipients
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- New insider Nundy Shantanu claimed no ownership of stock in the company (SEC Form 3)
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
Latest YDES
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- SEC Form 424B3 filed by YD Bio Limited
- SEC Form 6-K filed by YD Bio Limited
- YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
- YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
- YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations